# US 2011/0275698 A1 · "test and treat" strategy for treating transforming hpv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0275698 A1
- Document ID: US20110275698A1
- Status: Published application
- Kind: A1
- Application number: 12/776,643
- Filed: 2010-05-10
- Published: 2011-11-10
- Earliest claimed: 2010-05-10
- Assignees: Norchip A/S
- Inventors: Hanne Skomedal; Einar Morland; Geir Morland; Frank Karlsen
- Web page: https://patentgrep.com/patent/US20110275698A1

## CPC

- B23K 26/0096: {Portable laser equipment, e.g. hand-held laser apparatus}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/708: {for papilloma}
- F41H 13/0056: {for blinding or dazzling, i.e. by overstimulating the opponent's eyes or the enemy's sensor equipment}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- B23K: SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- F41H: ARMOUR; ARMOURED TURRETS; ARMOURED OR ARMED VEHICLES; MEANS OF ATTACK OR DEFENCE, e.g. CAMOUFLAGE, IN GENERAL

## Abstract

The invention is concerned with a “test and treat” method of screening and directly treating female subjects having transforming or abnormal human papillomavirus (HPV) infection.

## Claims

### Claim 1

A test and treat method of detecting and treating transforming infection with human papillomavirus (HPV) in a human female subject, the method consisting of:
testing a cervical sample from the subject for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
making a treatment decision in a female human subject based on the outcome of the test for expression of E6/E7 mRNA transcripts of said at least one cancer-associated (high-risk) or carcinogenic HPV type, whereby a subject whose cervical sample tests positive for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type is selected for direct treatment; and
treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).

### Claim 2 (depends on 1)

The method of claim 1 wherein the cervical sample is tested specifically for expression of full-length E6/E7 mRNA transcripts of at least one cancer-associated (high risk) or carcinogenic HPV type, which transcripts encode a full length E6 protein.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least one cancer-associated or carcinogenic HPV type selected from the group consisting of HPV types 5, 6, 8, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82.

### Claim 4 (depends on 1)

The method of claim 1 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV type 16.

### Claim 5 (depends on 1)

The method of claim 1 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16 and 18.

### Claim 6 (depends on 1)

The method of claim 1 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, and 45.

### Claim 7 (depends on 1)

The method of claim 1 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least one HPV type selected from the group consisting of HPV types 16, 18, 31, 33 and 45.

### Claim 8 (depends on 1)

The method of claim 1 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, 31, 33, 35, 45, 51, 52 and 58.

### Claim 9

A test and treat method of screening a population of female human subjects, selecting and treating individuals identified as having transforming infection with human papillomavirus (HPV) based on the outcome of a test for expression of E6/E7 mRNA transcripts of human papillomavirus (HPV), the method consisting of:
testing cervical samples from subjects in the population for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
making a treatment decision based on the outcome of the test for expression of E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type in cervical samples from said subjects, whereby a subject whose cervical sample tests positive for expression E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type is selected for direct treatment; and
treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).

### Claim 10 (depends on 9)

The method of claim 9 wherein the cervical samples are tested specifically for expression of full-length E6/E7 mRNA transcripts of at least one cancer-associated or carcinogenic HPV type, which transcripts encode a full length E6 protein.

### Claim 11 (depends on 9)

The method of claim 9 wherein the cervical samples are tested for expression of E6/E7 mRNA transcripts of at least one cancer-associated or carcinogenic HPV type selected from the group consisting of HPV types 5, 6, 8, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82.

### Claim 12 (depends on 9)

The method of claim 9 wherein the cervical samples are tested for expression of E6/E7 mRNA transcripts of at least HPV type 16.

### Claim 13 (depends on 9)

The method of claim 9 wherein the cervical samples are tested for expression of E6/E7 mRNA transcripts of at least HPV types 16 and 18.

### Claim 14 (depends on 9)

The method of claim 9 wherein the cervical samples are tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, and 45.

### Claim 15 (depends on 9)

The method of claim 9 wherein the cervical samples are tested for expression of E6/E7 mRNA transcripts of at least one HPV type selected from the group consisting of HPV types 16, 18, 31, 33 and 45.

### Claim 16 (depends on 9)

The method of claim 9 wherein the cervical samples are tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, 31, 33, 35, 45, 51, 52 and 58.

### Claim 17

A test and treat method of triaging female subjects having a previous diagnosis of ASC-US, low-grade cervical lesions (LSIL) or high-grade cervical lesions (HSIL) by cytology, selecting and treating individuals identified as having transforming infection with human papillomavirus (HPV) based on the outcome of a test for expression of E6/E7 mRNA transcripts of human papillomavirus (HPV), the method consisting of:
testing a cervical sample from a subject having a previous diagnosis of ASC-US, low-grade cervical lesions (LSIL) or high-grade cervical lesions (HSIL) by cytology for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
making a treatment decision based on the outcome of the test for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type in said cervical sample, whereby a subject whose cervical sample test positive for expression of E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type is selected for direct treatment; and
treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).

### Claim 18 (depends on 17)

The method of claim 17 wherein the cervical sample is tested specifically for expression of full-length E6/E7 mRNA transcripts of at least one cancer-associated (high risk) or carcinogenic HPV type, which transcripts encode a full length E6 protein.

### Claim 19 (depends on 17)

The method of claim 17 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least one HPV type selected from the group consisting of HPV types 5, 6, 8, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82.

### Claim 20 (depends on 17)

The method of claim 17 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV type 16.

### Claim 21 (depends on 17)

The method of claim 17 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16 and 18.

### Claim 22 (depends on 17)

The method of claim 17 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, and 45.

### Claim 23 (depends on 17)

The method of claim 17 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least one HPV type selected from the group consisting of HPV types 16, 18, 31, 33 and 45.

### Claim 24 (depends on 17)

The method of claim 17 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, 31, 33, 35, 45, 51, 52 and 58.

### Claim 25

A test and treat method of triaging female subjects who previously tested positive for the presence of DNA from at least one cancer-associated (high risk) or carcinogenic HPV type, selecting and treating individuals identified as having transforming infection with human papillomavirus (HPV) based on the outcome of a test for expression of E6/E7 mRNA transcripts of human papillomavirus (HPV), the method consisting of:
testing a cervical sample from a subject who previously tested positive for the presence of DNA from at least one cancer-associated (high risk) or carcinogenic HPV type for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
making a treatment decision based on the outcome of the test for expression of E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type in said cervical sample, whereby a subject whose cervical sample tests positive for expression E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type is selected for direct treatment; and
treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).

### Claim 26 (depends on 25)

The method of claim 25 wherein the cervical sample is tested specifically for expression of full-length E6/E7 mRNA transcripts of at least one cancer-associated or carcinogenic HPV type, which transcripts encode a full length E6 protein.

### Claim 27 (depends on 25)

The method of claim 25 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least one cancer-associated or carcinogenic HPV type selected from the group consisting of HPV types 5, 6, 8, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82.

### Claim 28 (depends on 25)

The method of claim 25 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV type 16.

### Claim 29 (depends on 25)

The method of claim 25 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16 and 18.

### Claim 30 (depends on 25)

The method of claim 25 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, and 45.

### Claim 31 (depends on 25)

The method of claim 25 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least one HPV type selected from the group consisting of HPV types 16, 18, 31, 33 and 45.

### Claim 32 (depends on 25)

The method of claim 25 wherein the cervical sample is tested for expression of E6/E7 mRNA transcripts of at least HPV types 16, 18, 31, 33, 35, 45, 51, 52 and 58.
